DAX24.490 +0,6%Est505.796 +0,8%MSCI World4.343 -0,1%Top 10 Crypto11,63 -0,5%Nas23.419 -0,2%Bitcoin75.307 +0,1%Euro1,1738 -0,1%Öl61,27 -1,0%Gold4.314 -0,6%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 DroneShield A2DMAA Bayer BAY001 Deutsche Telekom 555750 Novo Nordisk A3EU6F Lufthansa 823212 BYD A0M4W9 RENK RENK73 Allianz 840400 Infineon 623100 Siemens Energy ENER6Y Tesla A1CX3T BASF BASF11 Mercedes-Benz Group (ex Daimler) 710000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX beendet letzten Handelstag 2025 freundlich -- Rheinmetall, RENK, HENSOLDT & TKMS: Putin wirft Ukraine Terror vor -- TUI, Palantir, Meta im Fokus
Top News
ETF-Depot eröffnen: Was Anleger vor dem ersten Kauf wissen sollten ETF-Depot eröffnen: Was Anleger vor dem ersten Kauf wissen sollten
iPhone 17 Pro im Vodafone Business Prime L Tarif jetzt mit exklusivem Vorteil sichern iPhone 17 Pro im Vodafone Business Prime L Tarif jetzt mit exklusivem Vorteil sichern
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Castle Biosciences Aktie

Kaufen
Verkaufen
32,80 EUR ±0,00 EUR ±0,00 %
FSE
38,55 USD -0,76 USD -1,93 %
nachbörslich
BTT
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.975,69 Mio. EUR

KGV42,74Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2PNH3

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS14843C1053

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolCSTL

Castle Biosciences Aktien News

DatumMeistgelesen
BusinesswireStudy Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging
BusinesswireCastle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024
BusinesswireCastle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii®
BusinesswireCastle Biosciences’ Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report
BusinesswireCastle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BusinesswireStudy Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx®-Melanoma Test Results
BusinesswireCastle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting
BusinesswireCastle Biosciences Ranked Among the Top Workplaces in Houston by the Houston Chronicle for the Third Consecutive Year
BusinesswireReal-World Evidence Confirms IDgenetix®-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder
BusinesswireCastle Biosciences to Present at Upcoming Investor Conferences
BusinesswireCastle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx®-UM That Could Aid in the Early Detection of Uveal Melanomas
finanzen.netCastle Biosciences: Zahlen zum abgelaufenen Jahresviertel
BusinesswireEarly Discovery Data Shows Ability of Castle Biosciences’ Pipeline Program to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis Therapy
finanzen.netAusblick: Castle Biosciences stellt Zahlen zum jüngsten Quartal vor
BusinesswireCastle Biosciences to Present New Data on its TissueCypher® Barrett’s Esophagus Test at the 2023 American College of Gastroenterology Annual Scientific Meeting
BusinesswireCastle Biosciences to Release Third Quarter 2023 Financial Results and Host Conference Call on Thursday, Nov. 2
BusinesswireNew Data Highlights Clinical Utility and Performance of Castle Biosciences’ Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference®
BusinesswireDecisionDx®-Melanoma Outperforms Memorial Sloan Kettering Cancer Center (MSKCC) Nomogram in Predicting Sentinel Lymph Node Positivity in Patients with Cutaneous Melanoma
BusinesswireCastle Biosciences Shares New Data Demonstrating Ability of TissueCypher® Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett’s Esophagus
BusinesswireCastle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma
BusinesswireCastle Biosciences Ranked Third Among 2023 Top Workplaces in the Healthcare Industry
BusinesswireTissueCypher® Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus
BusinesswireCastle Biosciences Announces Receipt of New York Laboratory Permit for Pittsburgh Laboratory
BusinesswireTissueCypher® Provides Clinically-Impactful Risk Stratification in Patients with Barrett’s Esophagus
BusinesswireCastle Biosciences to Highlight Clinical Value of IDgenetix® Test at Psych Congress 2023
BusinesswireCastle Biosciences to Participate in Upcoming Investor Conferences
BusinesswireNew Publication Highlights the Ability of the TissueCypher® Barrett’s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus
finanzen.netCastle Biosciences öffnete die Bücher zum abgelaufenen Quartal
BusinesswireCastle Biosciences to Present at the Canaccord Genuity 43rd Annual Growth Conference
finanzen.netAusblick: Castle Biosciences veröffentlicht Zahlen zum vergangenen Quartal
BusinesswireCastle Biosciences to Release Second Quarter 2023 Financial Results and Host Conference Call on Wednesday, Aug. 2
BusinesswireCastle Biosciences to Host Second Annual Castle Cares Charity Walk
BusinesswireCastle Biosciences Honored as an Arizona Top Workplace for the Second Consecutive Year
BusinesswireCastle Biosciences to Present New DecisionDx®-SCC and DecisionDx®-Melanoma Data at the American Head & Neck Society’s (AHNS) 11th International Conference on Head and Neck Cancer
BusinesswireStudy Data from Castle Biosciences’ Collaboration with the National Cancer Institute’s SEER Program Registries Published in JCO Precision Oncology
BusinesswireCastle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BusinesswireCastle Biosciences to Share New Data on DecisionDx®-Melanoma and DecisionDx®-UM at the 2023 ASCO Annual Meeting
BusinesswireIDgenetix® Shown to Significantly Improve Medication Response and Remission Rates in Patients with Major Depressive Disorder
BusinesswireCastle Biosciences Celebrates Skin Cancer Awareness Month
BusinesswireCastle Biosciences’ Abstracts at Digestive Disease Week (DDW) Annual Meeting Selected as "Posters of Distinction” by the American Gastroenterological Association (AGA) Institute Council

Castle Biosciences News

Castle Biosciences News: auf dieser Seite finden Sie alle Castle Biosciences News und Nachrichten zur Castle Biosciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Castle Biosciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Castle Biosciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.